Management of Allergic Rhinitis: A Pharmacotherapy Update for the Pharmacist

Published Online: Monday, May 9, 2011
Follow Pharmacy_Times:
Pharmacy Times Office of Continuing Professional Education

Management of Allergic Rhinitis: A Pharmacotherapy Update for the Pharmacist

Nikhil Patel, PharmD, RPh, Director of Scientific Affairs, Pharmacy Times

Allergic rhinitis (AR) has been shown to affect 10% to 40% of the global population, and its prevalence is increasing in both children and adults. It has been shown to significantly reduce quality of life by impairing sleep and adversely affecting individuals’ social lives, school performance, and work productivity. Pharmacists are in a unique position to help patients with AR manage their condition, because they will be interacting with these patients on a frequent basis. This activity will review the treatments used to manage AR, including antihistamines, decongestants, intranasal corticosteroids, other inhaled medications, leukotriene receptor antagonists, and immunotherapy.

Educational Objectives

Upon completion of this educational activity, participants should be able to:
  1. Review the basic pathophysiology involved in allergic rhinitis (AR).
  2. Describe the common symptoms, presentation, and complications of AR.
  3. Discuss the available management options for AR, including avoidance and pharmacotherapy and their role in the treatment paradigm.
  4. Provide counseling and advice to help patients achieve optimal symptom relief.
Credits: 2.0
Expiration date: April 22, 2013.

Click here to view this lesson.
Related Articles
A former pharmacy technician thought the prescription pill records she was finagling were better shred than read.
A pharmacist testified before a Senate subcommittee today that unprecedented price hikes for formerly inexpensive generic prescription drugs are “wreaking havoc” on the health care system while jeopardizing the viability of community pharmacies.
After the Drug Enforcement Administration revoked the Tampa-based pharmacy’s registration to sell controlled substances and seized its drugs, the company fought back with a lawsuit.
Latest Issues